Equities research analysts predict that Nektar Therapeutics (NASDAQ:NKTR) will post sales of $25.89 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Nektar Therapeutics’ earnings, with estimates ranging from $24.50 million to $27.40 million. Nektar Therapeutics posted sales of $1.09 billion in the same quarter last year, which would indicate a negative year-over-year growth rate of 97.6%. The business is expected to issue its next earnings results on Wednesday, August 14th.
On average, analysts expect that Nektar Therapeutics will report full year sales of $107.47 million for the current year, with estimates ranging from $104.21 million to $111.92 million. For the next fiscal year, analysts expect that the company will post sales of $194.75 million, with estimates ranging from $115.24 million to $310.91 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The business had revenue of $28.22 million during the quarter, compared to analysts’ expectations of $25.45 million. During the same period in the previous year, the business earned ($0.60) earnings per share.
Several research firms recently commented on NKTR. Zacks Investment Research cut Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. BidaskClub cut Zebra Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. William Blair restated a “buy” rating on shares of Nektar Therapeutics in a research report on Friday, June 14th. Cowen set a $200.00 target price on Lululemon Athletica and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, ValuEngine cut Intersect ENT from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $68.50.
Nektar Therapeutics stock traded down $0.10 during midday trading on Friday, hitting $31.97. 1,017,889 shares of the company’s stock were exchanged, compared to its average volume of 1,372,475. Nektar Therapeutics has a 52-week low of $29.22 and a 52-week high of $69.76. The stock’s 50-day moving average price is $33.99. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. The firm has a market capitalization of $5.57 billion, a P/E ratio of 8.46 and a beta of 2.74.
In other news, SVP Stephen K. Doberstein sold 3,461 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $31.37, for a total value of $108,571.57. Following the completion of the transaction, the senior vice president now directly owns 95,913 shares in the company, valued at approximately $3,008,790.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lutz Lingnau sold 10,000 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $34.63, for a total value of $346,300.00. Following the completion of the transaction, the director now owns 33,200 shares of the company’s stock, valued at $1,149,716. The disclosure for this sale can be found here. Insiders sold a total of 219,949 shares of company stock valued at $7,285,900 over the last quarter. Company insiders own 4.02% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its holdings in Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 479 shares during the period. Quantamental Technologies LLC purchased a new stake in Nektar Therapeutics during the 1st quarter valued at about $27,000. CSat Investment Advisory L.P. boosted its holdings in Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 790 shares during the period. Gemmer Asset Management LLC boosted its holdings in Nektar Therapeutics by 476.8% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,390 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,149 shares during the period. Finally, Enterprise Financial Services Corp purchased a new stake in Nektar Therapeutics during the 1st quarter valued at about $67,000. Hedge funds and other institutional investors own 92.15% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Recommended Story: Why do company’s buyback their stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.